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BACKGROUND: It was recently found that cAMP mediates protein kinase A-independent effects through Epac proteins. The aim of this
study was to investigate the role of Epac in migration and proliferation of prostate carcinoma cells.
METHODS: The effect of Epac activation was determined by [
3H]thymidine incorporation and scratch assays in PC-3 and DU 145 cells.
Furthermore, cytoskeletal integrity was analysed by phalloidin staining. The participation of intracellular Epac effectors such as
mitogen-activated protein (MAP) kinases, Rap1- and Rho-GTPases was determined by immunoblotting and pull-down assay.
RESULTS: The specific Epac activator 8-pCPT-20-O-Me-cAMP (8-pCPT) interfered with cytoskeletal integrity, reduced DNA synthesis,
and migration. Although 8-pCPT activated Rap1, it inhibited MAP kinase signalling and RhoA activation. These findings were
translated into functional effects such as inhibition of mitogenesis, cytoskeletal integrity, and migration.
CONCLUSION: In human prostate carcinoma cells, Epac inhibits proliferative and migratory responses likely because of inhibition of
MAP kinase and RhoA signalling pathways. Therefore, Epac might represent an attractive therapeutic target in the treatment of
prostate cancer.
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Migration and proliferation are key events in cancer progression
and metastasis and the underlying molecular mechanisms of
interest for possible treatment options (Abate-Shen and Shen,
2000; Hao et al, 2007). It has been reported that progression of
prostate cancer, one of the leading causes of male cancer death, is
associated with an activation of members of the Ras family, which
in turn activate effectors, such as the mitogen-activated protein
kinases (MAPKs). In fact, elevated levels of the subfamily of
extracellular signal-regulated kinases 1 and 2 (ERK-1/2) could be
observed in advanced prostate tumours (Gioeli et al, 1999; Price
et al, 1999; Uzgare et al, 2003). In prostate carcinoma cells, cAMP
analogues, such as Bt2-cAMP or dbcAMP, not only inhibited
proliferation and migration but also induced cell differentiation
(Bang et al, 1992, 1994; Picascia et al, 2002; Chen et al, 2005),
thereby presenting potential new therapeutical treatment options.
For many years, these cAMP effects have been attributed solely
to the activation of protein kinase A (PKA) (Taylor et al, 1990).
However, recent studies have also shown the PKA-independent
effects of cAMP, suggesting a possible involvement of other cAMP
effectors, such as Epac (also known as cAMP-GEF (guanine
nucleotide exchange factors)), acting as GEFs for Rap and Ras
(Taylor et al, 1990; Bos, 2003; Holz et al, 2008). We and others have
recently shown that Epac proteins have an important role in
several cellular processes, including proliferation and apoptosis,
possibly by their signalling capacity to ERK and phosphoinositide-
3 kinase-dependent Akt (Fang and Olah, 2007; Grandoch et al,
2009). It is important that very recent studies could show an
involvement of Epac in cell migration (Mei and Cheng, 2005;
Yokoyama et al, 2008; Bastian et al, 2009), although the effects
(inhibitory or stimulatory) were not consistent.
Thus far, the role of Epac on migration and proliferation has not
been investigated in the prostate tumour cell lines PC-3 and DU
145. Therefore, we focused here on the question whether Epac
modulates those cellular functions in highly aggressive prostate
tumour cell lines with a high proliferative and metastasising
capacity.
MATERIALS AND METHODS
See also extended Materials and Methods section in Supplementary
materials (available online).
Cell culture and toxin treatment
PC-3 and DU 145 were cultured under standard conditions and
serum-deprived 12h before experiments. Clostridium difficile
toxin B (TcdB) was added for 24h at 10pgml
 1 (DU 145) or
100pgml
 1 (PC-3).
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After cell lysis (1% (vol/vol) SDS and 10mM Tris/HCl, pH 7.4),
proteins were separated by SDS–PAGE (10–15%), blotted onto
nitrocellulose, incubated with the indicated primary antibodies
(1:1000, 41C), and detected by the appropriate secondary
antibodies.
Mitogenesis and migration
DNA synthesis was measured using the [
3H]thymidine incorpora-
tion assay. Cell migration was determined in the presence of 1mM
hydroxy urea after scratch wounding of monolayer cultures.
Affinity precipitation of GTP-bound Rap1 and RhoA
Activated Rap1 or RhoA was extracted from cell lysates with
glutathione S-transferase-tagged RalGDS (Rap1) or Rhotekin
(RhoA), bound to Glutathione Sepharose beads. Immunoblotting
was performed with anti-Rap1 and anti-RhoA antibodies.
Immunofluorescence microscopy and flow cytometry
Cells were fixed (paraformaldehyde), permeablized (Triton X-100),
and stained for filamentous actin using AlexaFluor 488-conjugated
phalloidin. Cells were analysed microscopically and by flow
cytometry.
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Figure 1 Epac expression and functional characterisation in the human prostate cancer cell lines PC-3 and DU 145. Effects of the activation of adenylyl
cyclase and Epac on extracellular signal-regulated kinases 1 and 2 (ERK-1/2) phosphorylation, DNA synthesis, and migration. The effect of protein kinase A
(PKA) on cell migration. (A) Endogenously expressed Epac and PKA (western blotting) in PC-3 and DU 145 cells. (B) Specificity of the Epac activator
8-pCPT-20-O-Me-cAMP (8-pCPT; 300mM) as compared with the adenylyl cyclase activator forskolin (fors, 100mM) and the cAMP analogue dbcAMP (1mM)
as measured by the phosphorylation of vasodilator-activated phosphoprotein (VASP) (western blotting). (C and D) Effects of fors (100mM) and 8-pCPT
(300mM) on ERK-1/2 phosphorylation in PC-3 cells. Representative immunoblots and densitometrical analyses (means±s.e.m.) from n¼4 experiments are
shown, *Po0.05 vs control (con) (ANOVA/Bonferroni). (E) Effects of dbcAMP (1mM) and 8-pCPT (300mM) on DNA synthesis ([
3H]thymidine
incorporation). Data are means±s.e.m. from n¼4 experiments, *Po0.05 vs control (ANOVA/Bonferroni). (F) Effects of fors (100mM), 8-pCPT (300mM)
and H-89 (10mM) on cell migration in PC-3 cells. Microscopic analysis of the cell-free area was carried out at 0 and 24h and the area invaded by tumour cells
was calculated (migration margins are indicated). Original photographs (cell-free area indicated) and quantitative analysis (means±s.e.m.) of n¼3
experiments are shown, *Po0.05 vs control (ANOVA/Bonferroni). ANOVA, analysis of variance.
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Data are means±s.e.m. of n independent experiments. Statistical
significance was determined by one-way analysis of variance
followed by the Bonferroni test for multiple comparisons. Po0.05
was considered significant.
RESULTS
As shown in Figure 1A, PC-3 and DU 145 cells express Epac and
the different PKA catalytic and regulatory subunits. To control the
specificity of the Epac-specific activator 8-pCPT-20-O-Me-cAMP
(8-pCPT), we analysed the phosphorylation of vasodilator-
activated phosphoprotein (VASP), which is known to be
phosphorylated by PKA (Smolenski et al, 1998). Activation of
the adenylyl cyclase by forskolin (100mM) and treatment with
the cAMP analogue dbcAMP (1mM) induced VASP phosphoryla-
tion in both cell lines through PKA. In contrast, the Epac activator
8-pCPT (300mM) did not induce VASP phosphorylation
(Figure 1B).
Next we compared the effects of cAMP and 8-pCPT on the
phosphorylation of ERK-1/2 in PC-3 cells. Both, forskolin and
8-pCPT induced a slow, time-dependent decrease in basal ERK-1/2
phosphorylation (Figure 1C and D). To study possible functional
consequences of the Epac-mediated inhibition of the MAPK
pathway, we studied the effects of Epac activation on mitogenesis
in PC-3 and DU 145 cells. Both, dbcAMP (this cAMP analogue
was used because of inconsistent effects of forskolin in this
assay; data not shown) and 8-pCPT induced a significant decrease
in DNA synthesis (Figure 1E). In addition, both forskolin and
8-pCPT significantly inhibited cell migration of PC-3 and DU
145 cells (Figure 1F). Importantly, the PKA-inhibitor H-89
(10mM) showed no significant effects on the inhibition of cell
migration of PC-3 (Figure 1F) and DU 145 cells (data not
shown). Furthermore, inhibition of MEK by PD98059 (10mM) and
U0126 (10mM) also decreased cell migration and enhanced
the inhibitory effects of forskolin and 8-pCPT (data not shown)
in PC-3 cells.
Next, effects on the small GTPase Rap1, a downstream effector
of Epac, were analysed. Incubation with the PKA-specific cAMP
analogue 6-Bnz (500mM) led to a slight decrease in Rap1 activation,
whereas only the nonspecific 8-Bromo-cAMP (1mM) and the Epac-
activator 8-pCPT (300mM) activated the small GTPase at 5 and
10min, respectively (Figure 2A).
E-cadherin is highly relevant for cancer invasiveness (Behrens
et al, 1993) and has been shown to be regulated by Rap (for review
see, Price et al, 2004; Koistra et al, 2007). Thus, we next studied the
expression of E-cadherin in PC-3 and DU 145 cells in response to
8-pCPT (300mM) by immunoblotting (Figure 2B). However, the
Epac activator did not alter E-cadherin expression in the two cell
lines.
As cell migration is accompanied by a reorganisation of the
actin cytoskeleton, we also studied the cytoskeletal actin organisa-
tion by staining F-actin with phalloidin in PC-3 cells. Although in
control cells microscopically visible actin stress fibres could be
detected, treatment with forskolin (100mM) or 8-pCPT (300mM) led
to cell rounding accompanied by a disassembling of the stress
fibres with an irregular pattern and disruption into short
fragments (Figure 3A). These effects were confirmed by quanti-
tative analysis of F-actin as measured by flow cytometry
(Figure 3B). To elucidate the effect of Epac on Rho GTPases, we
performed RhoA activation assays. Lysophosphatidic acid (1mM)
was used as a positive control. Indeed, we could detect a decrease
in RhoA activation after treatment of PC-3 cells with the Epac
activator 8-pCPT (300mM; Figure 3C).
We confirmed the involvement of Rho-GTPases in the Epac-
activated signalling pathways using two Rho kinase inhibitors,
Y-27632 and HA-1077, respectively. Inhibition of Rho kinase by
Y-27632 (10mM) reversed 8-pCPT-induced inhibition of migration
in PC-3 and DU 145 cells (Figure 3D). Similar effects were also
detectable after inhibition of Rho kinase by HA-1077 (10mM; data
not shown). In addition, we used TcdB, a protein reported to
monoglucosylate members of the Rho protein family. After pre-
incubation of PC-3 and DU 145 cells for 24h with TcdB and
following stimulation with 8-pCPT, no inhibitory effects of the
Epac activator could be detected (Figure 3E).
DISCUSSION
This study is the first to show the anti-mitogenic and anti-
migratory effects of Epac activation in human prostate cancer cells.
Bang et al (1992) suggested that cAMP analogues might be
useful in the treatment of metastatic prostate cancer. However,
no discrimination between different possible cAMP effectors
has been made thus far, and for a long time PKA has been
assumed as the only cAMP target. Importantly, Epac proteins
have been shown to act as multifunctional regulators in different
cell functions, next to the canonical PKA pathway. Indeed, we
were able to detect Epac as well as PKA expression in PC-3 and DU
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Figure 2 Epac-dependent effects on E-cadherin expression. Activation
of Rap1 by 8-Bromo-cAMP, 6-Bnz, or 8-pCPT-20-O-Me-cAMP (8-pCPT).
(A) PC-3 and DU 145 cells were stimulated for the indicated periods of
time with (þ) or without ( ) 300mM 8-pCPT. Expression of E-cadherin in
whole-cell lysates was detected by western blotting. Equal loading was
shown by using b-Actin antibody. (B) Rap1 activation induced by 8-Bromo-
cAMP (1mM), 6-Bnz (500mM), or 8-pCPT (300mM) at 1, 5, and 10min
(pull-down/western blot).
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We confirmed inhibitory effects of cAMP on the phosphoryla-
tion level of ERK-1/2, mitogenesis, and migration (Price et al,
1999; Carey et al, 2007; Hao et al, 2007). Interestingly, we also
detected a significant inhibition of the MAPK signalling by the
specific Epac activator 8-pCPT. These findings were translated into
functional effects, such as an inhibition of mitogenesis and
migration.
As neither forskolin nor 8-pCPT induced apoptotic effects
in PC-3 cells (annexin V binding, caspase cleavage, PARP
processing; data not shown), we hypothesise that the obser-
ved inhibition of cell proliferation by these compounds most
likely depends on the inhibition of ERK-1/2-mediated mitogenic
events.
With regard to the anti-migratory effects of Epac activation in
PC-3 and DU 145 cells, our results are in line with recent findings
in ES-2 ovarian carcinoma cells (Bastian et al, 2009). The PKA
inhibitor H-89 was not able to prevent forskolin-induced inhi-
bition of cell migration strongly pointing to an Epac-dependent
signalling pathway. Interestingly, incubation of cells with the
inhibitor alone led to different outcomes in PC-3 vs DU 145 cells.
A reason for this might be the fact that H-89 is known to inhibit
even more target proteins than the well-known PKA (Davies et al,
2000).
Furthermore, Epac-dependent Rap1 activation is shown in
this study in PC-3 cells. However, no effect on E-cadherin
expression, which is known to be important for cancer cell
migration and tumour invasiveness (Behrens et al, 1993), could be
detected. This is in line with recent studies also describing
an Epac/Rap1-mediated inhibition of epithelial cell migration
independent of a modulation of the E-cadherin expression (Lyle
et al, 2008).
Importantly, our experiments support the conclusion that
inhibition of Rho GTPases, which are crucial for cell migration
(Raftopoulou and Hall, 2004) and invasion of PC-3 cells (Hodge
et al, 2003), might cause the anti-migratory effects of Epac.
Stimulation of Epac by 8-pCPT led to a complete disassembly of
the F-actin cytoskeleton. Furthermore, a decrease in RhoA
activation was also observed in a pull-down assay. These results
are in line with the described effects of cAMP analogues on RhoA
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Figure 3 Effects of forskolin and 8-pCPT-20-O-Me-cAMP (8-pCPT) on the actin cytoskeleton. (A) Effects of forskolin (100mM, 1h) or 8-pCPT (300mM,
1h) on filamentous actin (Alexa fluor 488-conjugated phalloidin staining). (B) Original FACS histograms and quantitative analysis of cellular Alexa fluor
488-conjugated phalloidin fluorescence. Data are means±s.e.m. from n¼3–5 independent experiments, *Po0.05 vs control (ANOVA/Bonferroni).
(C) Effects of forskolin (100mM, 1h) or 8-pCPT (300mM, 1h) on RhoA activation (pull-down/western blot). (D) Effects of the Rho kinase inhibitor Y-27632
on cell migration of PC-3 and DU 145 cells. Pre-incubation with Y-27632 (10mM) for 20min was followed by stimulation of the cells with 8-pCPT (300mM).
Microscopic analysis of the cell-free area was carried out at 0 and 24h, and the area invaded by tumour cells was calculated and quantitative analysis
(means±s.e.m.) of n¼3 experiments are shown, *Po0.05 vs control (ANOVA/Bonferroni). (E) Effects of toxin B on cell migration in PC-3 and DU 145
cells. Cells were incubated for 24h with Clostridium difficile toxin B (TcdB; 10 and 100pgml
 1) before stimulation with the indicated agents and microscopic
analysis of the cell-free area at 0 and 24h. The area invaded by the tumour cells was calculated. Quantitative analysis (means±s.e.m.) of n¼3 experiments
are shown, *Po0.05 vs control (ANOVA/Bonferroni). ANOVA, analysis of variance.
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and RhoA (Chen et al, 2005).
In summary, this study shows for the first time anti-prolifera-
tive and anti-migratory effects of Epac activation in human
prostate cancer cells, presumably mechanistically explained by an
inhibition of the MAP kinases and RhoA. As these cellular
functions are crucial for tumour growth and metastasis, Epac
might represent an attractive therapeutic target in the treatment of
prostate cancer.
ACKNOWLEDGEMENTS
We thank B Langer and S Metze for technical assistance. We also
thank H Genth and C von Eichel-Streiber for providing
Clostridium difficile toxin B.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc).
REFERENCES
Abate-Shen C, Shen MM (2000) Molecular genetics of prostate cancer.
Genes Dev 140: 2410–2434
Bang J, Kim SJ, Danielpour D, Oreilly MA, Kim KY, Myers CE, Trepel JB
(1992) Cyclic-AMP induces transforming growth-factor-beta-2 gene-
expression and growth arrest in the human androgen-independent
prostate carcinoma cell-line Pc-3. Proc Natl Acad Sci USA 89: 3556–3560
Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ,
Tsokos M, Sheahan MD, Nguyen P, Niklinski WT, Myers CE, Trepel JB
(1994) Terminal neuroendocrine differentiation of human prostate
carcinoma-cells in response to increased intracellular cyclic-AMP. Proc
Natl Acad Sci USA 91: 5330–5334
Bastian P, Balcarek A, Altanis C, Strell C, Niggemann B, Zaenker KS,
Entschladen F (2009) The inhibitory effect of norepinephrine on the
migration of ES-2 ovarian carcinoma cells involves a Rap1-dependent
pathway. Cancer Lett 274: 218–224
Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM,
Birchmeier W (1993) Loss of epithelial differentiation and gain of
invasiveness correlates with tyrosine phosphorylation of the E-cadherin/
beta-Catenin complex in cells transformed with a temperature-sensitive
v-SRC gene. J Cell Biol 20: 757–766
Bos JL (2003) Epac: a new cAMP target and new avenues in cAMP research.
Nat Rev Mol Cell Biol 4: 733–738
Carey AM, Pramanik R, Nicholson LJ, Dew TK, Martin FL, Muir GH, Morris
JDH (2007) Ras–MEK–ERK signaling cascade regulates androgen
receptor element-inducible gene transcription and DNA synthesis in
prostrate cancer cells. Int J Cancer 121: 520–527
Chen YC, Wang Y, Yu H, Wang FW, Xu WR (2005) The cross talk between
protein kinase A- and RhoA-mediated signaling in cancer cells. Exp Biol
Med 230: 731–741
Davies SP, Reddy H, Calvano M, Cohen P (2000) Specificity and mechanism
of action of some commonly used protein kinase inhibitors. Biochem J
351: 95–105
Fang Y, Olah ME (2007) Cyclic AMP-dependent, protein kinase A-
independent activation of extracellular signal-regulated kinase 1/2
following denosine receptor stimulation in human umbilical vein
endothelial cells: role of exchange protein activated by cAMP 1 (Epac1).
J Pharmacol Exp Ther 322: 1189–1200
Gioeli D, Mandell JW, Petroni GR, Frierson HF, Weber MJ (1999)
Activation of mitogen-activated protein kinase associated with prostate
cancer progression. Cancer Res 59: 279–284
Grandoch M, Lo ´pez de Jesu ´s M, Oude Weernink PA, Weber A-A, Jakobs
KH, Schmidt M (2009) B cell receptor-induced growth arrest and
apoptosis in WEHI-231 immature B lymphoma cells involve cyclic AMP
and Epac proteins. Cell Signal 21: 609–621
Hao F, Tan M, Xu X, Han J, Miller DD, Tigyi G, Cui MZ (2007) Lyso-
phosphatidic acid induces prostate cancer PC3 cell migration via activa-
tion of LPA(1), p42 and p38 alpha. Biochim Biophys Acta 1771: 883–892
Hermann A, Schro ¨r K, Weber A-A (2002) CD40 ligand (CD40L) does not
stimulate proliferation of vascular smooth muscle cells. Eur J Cell Biol 81:
213–221
Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A, Lindholm PF (2003)
Requirement of RhoA activity for increased nuclear factor kappa B
activity and PC-3 human prostate cancer cell invasion. Cancer Res 63:
1359–1364
Holz GG, Chepurny OG, Schwede F (2008) Epac-selective cAMP
analogs: new tools with which to evaluate the signal transduction
properties of cAMP-regulated guanine nucleotide exchange factors.
Cell Signal 20: 10–20
Koistra MR, Dube ´ N, Bos JL (2007) Rap1: a key regulator in cell–cell
junction formation. J Cell Sci 120: 17–22
Lyle KS, Raaijkmakers JH, Bruinsma W, Bos JL, de Rooij J (2008) cAMP-
induced Epac-Rap activation inhibits epithelial cell migration by
modulating focal adhesion and leading edge dynamics. Cell Signal 20:
1104–1116
Mei FC, Cheng XD (2005) Interplay between exchange protein directly
activated by cAMP (Epac) and microtubule cytoskeleton. Mol Biosyst 1:
325–331
Picascia A, Stanzione R, Chieffi P, Kisslinger A, Dikic I, Tramontano D
(2002) Proline-rich tyrosine kinase 2 regulates proliferation and
differentiation of prostate cells. Mol Cell Endocrinol 186: 81–87
Price DT, Della Rocca G, Guo CH, Ballo MS, Schwinn DA, Luttrell LM
(1999) Activation of extracellular signal-regulated kinase in human
prostate cancer. J Urol 162: 1537–1542
Price LS, Hajdo-Milasinovic A, Zhao J, Zwartkruis FJT, Collard JG, Bos JL
(2004) Rap1 regulates E-cadherin-mediated cell–cell-adhesion. J Biol
Chem 279: 35127–35132
Raftopoulou M, Hall A (2004) Cell migration: Rho GTPases lead the way.
Dev Biol 265: 23–32
Smolenski A, Bachmann C, Reinhard K, Ho ˜nig-Liedl P, Jarchau T,
Hoschuetzky H, Walter U (1998) Analysis and regulation of vasodila-
tor-stimulated phosphoprotein serin 239 phosphorylation in vitro and in
intact cells using a phosphospecific monoclonal antibody. J Biol Chem
273: 20029–20035
Taylor SS, Buechler JA, Yonemoto W (1990) cAMP-dependent protein-
kinase – framework for a diverse family of regulatory enzymes. Annu Rev
Biochem 59: 971–1005
Uzgare R, Kaplan PJ, Greenberg NM (2003) Differential expression and/or
activation of p38MAPK, Erkl/2, and Jnk during the initiation and
progression of prostate cancer. Prostate 55: 128–139
Yokoyama U, Minamisawa S, Quan H, Akaike T, Jin MH, Otsu K, Ulucan C,
Wang X, Baljinnyam E, Takaoka M, Sata M, Ishikawa Y (2008) Epac1 is
upregulated during neointima formation and promotes vascular
smooth muscle cell migration. Am J Physiol Heart Circ Physiol 295:
H1547–H1555
Anti-mitogenic and anti-migratory role of prostate cancer
M Grandoch et al
2042
British Journal of Cancer (2009) 101(12), 2038–2042 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s